Sepsis
Recent clinical, regulatory, research and industry developments relating to this disease.
Global, regional, and national sepsis incidence and mortality, 1990-2021: a systematic analysis.
AI-driven multi-omics profiling of sepsis immunity in the digestive system.
Megakaryocyte in sepsis: the trinity of coagulation, inflammation and immunity.
Lactate's impact on immune cells in sepsis: unraveling the complex interplay.
The role of trained immunity in sepsis.
Altered DNA methylation underlies monocyte dysregulation and immune exhaustion memory in sepsis.
Post-sepsis psychiatric disorder: Pathophysiology, prevention, and treatment.
A pairwise cytokine code explains the organism-wide response to sepsis.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q2 2027.
- Active recent publication activity.
- Q2 2027A Prospective, Single-center, Randomized, Double-blind Controlled Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation
- Q2 2028Aminoglycosides in Early Sepsis (AGES): A Randomized Pragmatic Clinical Trial Comparing Gentamicin and Narrow Spectrum Betalactams to Broad Spectrum Betalactams as Empirical Treatment in Patients With Suspected Sepsis
- Q2 2028Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS (TRIPS)
- Q2 2029Reduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure: a Multicenter, Open-label, Phase IIb Randomized Controlled Trial
Research HighlightsViewHide
Clinical MilestonesView all 9Hide
- 2026-06-05Reduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure: a Multicenter, Open-label, Phase IIb Randomized Controlled TrialResults expected Q2 2029
- 2026-04-24Aminoglycosides in Early Sepsis (AGES): A Randomized Pragmatic Clinical Trial Comparing Gentamicin and Narrow Spectrum Betalactams to Broad Spectrum Betalactams as Empirical Treatment in Patients With Suspected SepsisResults expected Q2 2028
- 2026-03-13Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS (TRIPS)Results expected Q2 2028
- 2026-01-15A Prospective, Single-center, Randomized, Double-blind Controlled Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota TransplantationResults expected Q2 2027
- 2026-01-31Small Volume Fluid Resuscitation and Supplementation With 20% albumIn Versus Buffered Crystalloids in PatiEnts With Septic ShockCompleted
- 2025-11-17Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP)Completed
- 2025-09-10GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODSCompleted
- 2029-12-31ClinicalPhase 3 Randomized, Blinded, Placebo-Controlled Study Evaluating Nogapendekin Alfa Inbakicept and iNKT Cells In Critically Ill Adults With Severe Community-Acquired Pneumonia With or Without Sepsis/Acute Respiratory Distress SyndromeWithdrawn
- 2026-06-05ClinicalReduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure: a Multicenter, Open-label, Phase IIb Randomized Controlled TrialResults expected Q2 2029
- 2026-04-24ClinicalAminoglycosides in Early Sepsis (AGES): A Randomized Pragmatic Clinical Trial Comparing Gentamicin and Narrow Spectrum Betalactams to Broad Spectrum Betalactams as Empirical Treatment in Patients With Suspected SepsisResults expected Q2 2028
- 2026-03-13ClinicalTargeted Reversal of Inflammation in Pediatric Sepsis-induced MODS (TRIPS)Results expected Q2 2028
- 2026-02-05ClinicalThe Effect of Vitamin D Administration on Sepsis Score and C-Reactive Protein Levels in Preterm Infants With Neonatal SepsisResults posted
- 2026-01-31ClinicalSmall Volume Fluid Resuscitation and Supplementation With 20% albumIn Versus Buffered Crystalloids in PatiEnts With Septic ShockCompleted
- 2026-01-15ClinicalA Prospective, Single-center, Randomized, Double-blind Controlled Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota TransplantationResults expected Q2 2027
- 2025-11-17ClinicalParamedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP)Completed
- 2025-10-21ResearchGlobal, regional, and national sepsis incidence and mortality, 1990-2021: a systematic analysis.2025
- 2025-09-10ClinicalGM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODSCompleted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Sepsis31
- Cell-Free Nucleic Acids2
- Extracellular Traps2
- High-Throughput Nucleotide Sequencing2
- Immunity, Innate2
- Inflammation2
- Shock, Septic2
- Acute Kidney Injury1
Leading journals6
- Frontiers in immunology9
- Critical care medicine3
- Critical care (London, England)2
- Frontiers in cellular and infection microbiology2
- International journal of molecular sciences2
- Lancet (London, England)2
Leading researchers8
- Angus DC5
- Alhazzani W3
- Annane D3
- Dellinger RP3
- Levy MM3
- Li J3
- Machado FR3
- Seymour CW3
Affiliations (unnormalised)6
- Brigham and Women's Hospital3
- Australian and New Zealand Intensive Care Research Centre2
- Bloomsbury Institute of Intensive Care Medicine2
- Center for Sepsis Control and Care2
- Department of Laboratory Medicine2
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell2
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Sepsis is a systemic inflammatory response syndrome caused by a proven or suspected infection. It can progress to severe sepsis when organ dysfunction develops distant from the infection site, and to septic shock when hypotension persists despite adequate fluid infusion.
The grounding supports an infectious etiology, with sepsis arising from a proven or suspected infection. It also indicates that bacterial pathogens are relevant in sepsis-associated inflammatory complications, including pneumonia and acute lung injury.
Sepsis involves a dysfunctional host response to infection with widespread activation of inflammatory mediators, immune pathways, and the hemostatic system. The literature highlights endothelial dysfunction, altered hemodynamics, cytokine signaling, innate immunity, apoptosis, and cell-free nucleic acids as part of the biological response, with organ dysfunction reflecting this systemic process.
The supplied grounding does not identify specific patient-level risk factors for developing sepsis. It does indicate that infectious stimuli, including bacterial infection and pneumonia, are associated with sepsis and sepsis-related organ injury.
Management is described at the level of guideline-based care for sepsis and septic shock, with emphasis on hemodynamic support, infection management, adjunctive therapies, metabolic management, and ventilation. The grounding also supports drug therapy and targeted therapeutic approaches, but does not specify individual drug classes beyond general treatment categories.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.